Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma

MLA

Gloria Cimaglia, et al. “Oral Nicotinamide Provides Robust, Dose-Dependent Structural and Metabolic Neuroprotection of Retinal Ganglion Cells in Experimental Glaucoma.” Acta Neuropathologica Communications, vol. 12, no. 1, Aug. 2024, pp. 1–17. EBSCOhost, https://doi.org/10.1186/s40478-024-01850-8.

APA

Gloria Cimaglia, James R. Tribble, Marcela Votruba, Pete A. Williams, & James E. Morgan. (2024). Oral nicotinamide provides robust, dose-dependent structural and metabolic neuroprotection of retinal ganglion cells in experimental glaucoma. Acta Neuropathologica Communications, 12(1), 1–17. https://doi.org/10.1186/s40478-024-01850-8

Chicago

Gloria Cimaglia, James R. Tribble, Marcela Votruba, Pete A. Williams, and James E. Morgan. 2024. “Oral Nicotinamide Provides Robust, Dose-Dependent Structural and Metabolic Neuroprotection of Retinal Ganglion Cells in Experimental Glaucoma.” Acta Neuropathologica Communications 12 (1): 1–17. doi:10.1186/s40478-024-01850-8.